Galectin Therapeutics reported $27.65M in Assets for its fiscal quarter ending in June of 2024.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Galectin Therapeutics USD 27.65M 1.76M Jun/2024
Gilead Sciences USD 56.28B 2.74B Mar/2026
Immunic USD 189.74M 165.69M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Merck USD 128.68B 8.18B Mar/2026